, Singapore
549 views
Photo via Pexels

Synapxe, A*STAR partner for health tech innovation in Singapore

The agencies will develop a pilot project to onboard APOLLO onto AimSG.

Singapore's HealthTech agency Synapxe and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to drive collaboration and scalable innovation within Singapore's healthcare ecosystem.

The MoU aims to address common challenges in healthcare administration, identify emerging technologies, and co-create scalable solutions for deployment into the healthcare system.

Under the partnership, the agencies will develop a pilot project to onboard APOLLO onto AimSG, a common platform for the rapid development, testing, and deployment of artificial intelligence (AI) imaging models. 

APOLLO, an AI-enabled CT scan interpretation software, has demonstrated its ability to slash manual CT scan interpretation time, typically ranging from one to four hours, to under 10 minutes. It was co-developed by A*STAR together with its partners Duke-NUS Medical School, Nanyang Technological University, National Heart Centre Singapore, National University Hospital, and Tan Tock Seng Hospital.

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.